Computational study on novel natural inhibitors targeting BCL2

Area of Science:

• Medicinal Chemistry
• Computational Drug Discovery
• Oncology

Background:

• Diffuse large B-cell lymphoma (DLCBL) is a significant hematological malignancy.
• Targeting BCL2 is a validated therapeutic strategy for DLCBL.
• Novel BCL2 inhibitors are needed for improved drug development.

Purpose of the Study:

• To identify novel, safe, and effective BCL2 inhibitors for DLCBL treatment.
• To lay the foundation for drug development and compound improvement for DLCBL.

Main Methods:

• Virtual screening of the ZINC database using Libdock.
• Absorption, distribution, metabolism, and excretion (ADME) and toxicity predictions.
• Molecular docking and molecular dynamics simulations to assess binding affinity and stability.

Main Results:

• Identified two natural compounds, ZINC00000255131 and ZINC00013298233, as potential BCL2 inhibitors.
• These compounds demonstrated favorable safety profiles, including low mutagenicity and carcinogenicity.
• Molecular dynamics confirmed stable binding interactions between the compounds and BCL2.

Conclusions:

• ZINC00000255131 and ZINC00013298233 are promising lead compounds for DLCBL drug development.
• The identified compounds possess favorable safety and binding characteristics.
• This study provides a strong basis for further development of BCL2-targeted therapies for DLCBL.